Akebia Therapeutics, Inc. (AKBA) compared with its closest peers (EBS, MGNX, PYXS, NATR, GLSI). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Emergent BioSolutions Inc. (EBS) | $262.37M | 2.3 |
| MacroGenics, Inc. (MGNX) | $257.35M | -1.4 |
| Pyxis Oncology, Inc. (PYXS) | $256.06M | -0.9 |
| Nature's Sunshine Products, Inc. (NATR) | $252.32M | 13.2 |
| Greenwich LifeSciences, Inc. (GLSI) | $244.32M | — |
| Sionna Therapeutics, Inc. (SION) | $238.27M | -21.9 |
| Whitehawk Therapeutics Inc (WHWK) | $233.91M | -7.3 |
| Organogenesis Holdings Inc. (ORGO) | $231.61M | 34.5 |
| Minerva Neurosciences, Inc. (NERV) | $230.14M | -0.1 |
| Avidity Biosciences, Inc. (RNA) | $226.39M | -14.5 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
AKBA overview · AKBA earnings · AKBA financials · AKBA KPIs · AKBA investor relations · AKBA ownership · AKBA filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.